Clinical trials: Wart
Verruca Viral
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
Common warts are papulonodular epidermal lesions caused by human papillomavirus (HPV) usually by the strains 1, 2, 4, 27 or 57. Cutaneous warts occur in 7% to 10% of the general population, with a maximum incidence between 12 and…
- Trial name
- MMR (NCT04428359)
- Testing
- Measles-Mumps-Rubella Vaccine, Vit D
- Where
- Nepal
- Volunteers
- 66 people
- Sponsor
- B.P. Koirala Institute of Health Sciences
Genital Warts
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW.
- Trial name
- NCT00674739
- Testing
- Imiquimod, 3.75% imiquimod cream
- Where
- 30 sites in United States
- Volunteers
- 470 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Warts, Anal Cancer
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women.
- Conditions
- Genital Warts, Anal Cancer, Anal Intraepithelial Neoplasia
- Trial name
- NCT01651949
- Testing
- 9vHPV Vaccine
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cutaneous Common Warts
A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts
To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).
- Trial name
- NCT02971891
- Testing
- CLS006 (Furosemide) Topical Gel, Vehicle Topical Gel
- Where
- 30 sites in United States
- Volunteers
- 484 people
- Sponsor
- Maruho Co., Ltd.
Myelokathexis, Infections
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
Background: WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is a rare disease. It can cause cancers, infections, and warts. Researchers want to see if a drug called plerixafor can treat WHIMS.
- Conditions
- Myelokathexis, Infections, Neutropenia, Warts
- Trial name
- NCT02231879
- Testing
- Plerixafor, G-CSF
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Warts, Genital, Neoplasms, Anal
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)
The purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate the efficacy of V503 in preventing human papillomavirus (HPV)-related anogenital persistent infection, and to evaluate the…
- Trial name
- NCT04635423
- Testing
- V503
- Where
- 22 sites in Japan
- Volunteers
- 1,059 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Genital Warts
Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)
The primary purpose of the study is to determine if an investigational vaccine Gardasil (V501) with 4 components will provide an immune response and will be well tolerated in pre-adolescents and adolescents.
- Trial name
- NCT00092495
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 3,055 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Common Wart
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
- Trial name
- NCT03812510
- Testing
- A-101
- Where
- 46 sites in United States
- Volunteers
- 426 people
- Sponsor
- Aclaris Therapeutics, Inc.
Verruca, Warts
Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study
The purpose of this study is to investigate topical treatment with Veregen™ 15% ointment as a single therapeutic agent and compare it to combination therapy with Veregen ™ 15% ointment and a single destructive treatment by…
- Trial name
- NCT02622568
- Testing
- Veregen only, Cryotherapy and Veregen
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In…
- Trial name
- NCT00092521
- Testing
- V501, Human Papillomavirus (HPV) 16 Monovalent
- Volunteers
- 5,759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts
Primary, Secondary, and Exploratory Objective(s): Primary objective: To evaluate the effect of interventions on 1st dose uptake of HPV vaccine.
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02551887
- Testing
- Automated Reminder, Automated Reminder Plus Script
- Volunteers
- 647 people
- Sponsor
- Regenstrief Institute, Inc.
Genital Warts, Human Papilloma Virus
Typing of Human Papilloma Virus (HPV) From Female Genital Warts
This is a longitudinal observational study of women presenting to Groote Schuur Hospital with genital warts. The study will evaluate the socio-demographic characteristics of the women using a structured questionnaire.
- Trial name
- NCT01192282
- Testing
- Medical / Surgical Treatment
- Where
- South Africa
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
The purpose of this study was to evaluate the safety, efficacy, and immunogenicity of V503 in comparison to GARDASIL. The primary hypotheses tested in the study were 1) V503 administered to 16- to 26-year-old adolescents and…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00543543
- Testing
- Comparator: GARDASIL, Experimental: V503
- Volunteers
- 14,840 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Verruca Vulgaris, Molluscum Contagiosum Skin Infection
Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum.
- Trial name
- NCT05070754
- Testing
- Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP), Cryotherapy, Canthardin Collodion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical University of South Carolina
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Hpv
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
The purpose of the study is to understand if children with liver and kidney transplants develop the antibodies from the Gardasil vaccine.
- Conditions
- Cervical Cancer, Hpv, Warts
- Trial name
- NCT01101750
- Testing
- Quadrivalent HPV for types 6, 11, 16 and 18
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Medstar Health Research Institute
Condylomata Acuminata
An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)
This study was conducted to demonstrate that Gardasil™ (quadrivalent human papillomavirus [qHPV] vaccine) 1) is well tolerated in young men, 2) reduces incidence of external genital lesions in young men, 3) reduces the incidence…
- Trial name
- NCT00090285
- Testing
- (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 4,065 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Warts
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW.
- Trial name
- NCT00735462
- Testing
- 2.5% imiquimod cream, 3.75% imiquimod cream
- Where
- 43 sites in United States
- Volunteers
- 511 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.
- Trial name
- FUTURE II (NCT00092534)
- Testing
- Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 12,167 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC